Late-stage Product Development. Too early to predict impact of biosimilars on utilization of hematopoietic growth factors.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Works matching IS 1082801X AND DT 2011 AND VI 46 AND IP 4
Results: 19
1
2
FDA Drug Approvals. New indication.
- Published in:
- 2011
- Publication type:
- Journal Article
3
Drug Watch. Type 1 diabetes mellitus.
- Published in:
- Formulary, 2011, v. 46, n. 4, p. 152
- By:
- Publication type:
- Article
4
Policy Watch. Health reform controversies pose new challenges for drug plans and healthcare providers.
- Published in:
- Formulary, 2011, v. 46, n. 4, p. 150
- By:
- Publication type:
- Article
5
Meeting Coverage. Intensive glycemic management leads to higher mortality in T2DM patients.
- Published in:
- 2011
- By:
- Publication type:
- Proceeding
6
Medication Safety and Reliability. FDA continues its review of abacavir: Evidence does not suggest an increased risk of myocardial infarction.
- Published in:
- Formulary, 2011, v. 46, n. 4, p. 148
- Publication type:
- Article
7
Medication Safety and Reliability. Lopinavir/ritonavir label change warns of serious risks in premature babies.
- Published in:
- Formulary, 2011, v. 46, n. 4, p. 147
- Publication type:
- Article
8
Medication Safety and Reliability. FDA warns of risks associated with the use of antipsychotic medications in pregnancy.
- Published in:
- Formulary, 2011, v. 46, n. 4, p. 147
- Publication type:
- Article
9
Metastatic breast cancer: A review of current and novel pharmacotherapy.
- Published in:
- Formulary, 2011, v. 46, n. 4, p. 130
- By:
- Publication type:
- Article
10
Belimumab: A B-lymphocyte stimulator inhibitor for systemic lupus erythematosus.
- Published in:
- Formulary, 2011, v. 46, n. 4, p. 118
- By:
- Publication type:
- Article
11
Cost of heart failure drugs impacts medication adherence.
- Published in:
- Formulary, 2011, v. 46, n. 4, p. 114
- Publication type:
- Article
12
For now FDA will continue to allow pharmacies to provide compounded hydroxyprogesterone caproate.
- Published in:
- Formulary, 2011, v. 46, n. 4, p. 114
- Publication type:
- Article
13
Brand-name, generic antidepressants share similar discontinuation rates and healthcare costs during 6 months of treatment.
- Published in:
- Formulary, 2011, v. 46, n. 4, p. 113
- Publication type:
- Article
14
New guidelines for AF management incorporate dabigatran.
- Published in:
- Formulary, 2011, v. 46, n. 4, p. 112
- Publication type:
- Article
15
Ambulatory blood pressure lowering efficacy of HCTZ inferior to other drug classes.
- Published in:
- Formulary, 2011, v. 46, n. 4, p. 112
- Publication type:
- Article
16
FDA actions in brief.
- Published in:
- Formulary, 2011, v. 46, n. 4, p. 106
- Publication type:
- Article
17
Menovo.
- Published in:
- Formulary, 2011, v. 46, n. 4, p. 105
- Publication type:
- Article
18
Makena.
- Published in:
- Formulary, 2011, v. 46, n. 4, p. 105
- Publication type:
- Article
19
FDA Drug Approvals. Pipeline preview.
- Published in:
- Formulary, 2011, v. 46, n. 4, p. 105
- Publication type:
- Article